Effects of Rosuvastatin on serum IL-6 and hs-CRP and on treatment of unstable angina pectoris

Objective To observe the clinical effect of Rosuvastatin in the treatment of unstable anginapectoris(UAP) and the clinical efficacy of IL-6 and hs-CRP changes. Methods 98 cases of UAP patients were randomly divided into two groups. 48 cases of control group were were given conventional treatment; 50 cases of treatment group given oral rosuvastatin based on the control group treatment. Both groups were treated for 8weeks. Results After the treatment,the treatment group improvement of angina pectoris and ECG were significantly better than that of the control group(Pl ＜ 0.05). In treatment group, serum IL-6 and hs-CRP were significantly lower than those the control group(P ＜ 0.05 ). Treatment group had no obvious adverse reactions. Conclusion Rosuvastatin treatment of UAP can improve symptoms of angina and ischemic ECG changes, have a significant reduction in serum IL-6 and hs-CRP concentrations,and no significant adverse reactions. Key words: Rosuvastatin; Unstable angina pectoris; Interleukin-6 (IL-6); High-sensitivity C-reactive protein(hs-CRP)